 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
3 News |  |
- || JNJ-61178104 / J&J
Clinical, PK/PD data, Journal: Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects. (Pubmed Central) - Aug 5, 2020
The time to reach mean maximum serum total TNFα and total IL-17A concentrations appeared to be dose dependent across the 0.1 mg/kg to 10 mg/kg IV dose groups. All subjects who received active treatment were antidrug antibody positive after dosing with JNJ-61178104.
- | JNJ-61178104 / J&J
Journal: Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A. (Pubmed Central) - Jun 17, 2020
These findings show that in vivo target engagement of monovalent bispecific antibody does not necessarily recapitulate that of the molar-equivalent dose of its bivalent parental antibody. Our results also offer valuable insights into the understanding of the pharmacokinetics/pharmacodynamics and target engagement of other bispecific biologics against dimeric and/or trimeric soluble targets in vivo.
- ||| JNJ-61178104 / J&J
Trial completion: A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants (clinicaltrials.gov) - Jan 23, 2017
P1, N=54, Completed, Sponsor: Janssen Research & Development, LLC
Our results also offer valuable insights into the understanding of the pharmacokinetics/pharmacodynamics and target engagement of other bispecific biologics against dimeric and/or trimeric soluble targets in vivo. Recruiting --> Completed
- ||| JNJ-61178104 / J&J
Enrollment open: A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants (clinicaltrials.gov) - Jun 2, 2016
P1, N=54, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| JNJ-61178104 / J&J
New P1 trial: A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants (clinicaltrials.gov) - May 2, 2016
P1, N=54, Not yet recruiting, Sponsor: Janssen Research & Development, LLC